Podium to Practice: ASH® 2025 – LYMPHOMA: First Phase III Comparison of Non-Covalent vs. Covalent BTKi in CLL/SLL
OR
[magic_login_form]
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
ID 683 – Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
This program has been made possible through unrestricted support from Eli Lilly and Merck.
Studies/trials discussed:
ID 683 – Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.